Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Stryker Corporation

Rank #178Capital ReturnWatchlistCompare with other stocks

SYK · NYSE · Healthcare

Stryker Corporation (SYK) — Rank #178 by gross profitability (GP/assets 0.34) · ROE 13.5% · Piotroski F-Score 4 / 9.

As-of 2026-10-30 · CIK 0000310764 · all metrics point-in-time as of the filing date.

About

Stryker Corporation operates as a medical technology company in the United States and internationally.

Show more

It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries.

Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Industry
Medical Devices
Sector
Healthcare
State
MI
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

56,000

Industry

Medical Devices

Exchange

NYSE

12/12

Flags passed

SYK passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Operating leverage expanding · Deferred revenue growing · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.34
Return on equity
13.5%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.00
Current ratio
2.16×
Net cash
-$11.47B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
1.0%

Growth

2/2 pass
Revenue growth
11.2%
Piotroski F-Score
4 / 9
Share dilution
0.2%

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 37th percentile of 20 SIC 3841 peers

Gross profitability (GP / assets)

0.34

Primary signal (Novy-Marx).

37th pctl of 20 SIC 3841 peers

Return on equity

13.5%

Gross margin

64.0%

47th pctl of 20 SIC 3841 peers

Revenue growth (YoY)

11.2%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

10.8%

Revenue CAGR (5Y)

11.8%

Earnings CAGR (3Y)

11.2%

FCF CAGR (3Y)

28.1%

Cash Flow Health

Is the cash real?

No warning flags · FCF 32% above net income

Free cash flow

$4.28B

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

31.9%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.0%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net debt $11.47B, F-Score 4/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.00

15th of 19 SIC 3841 peers (best = lowest)

Current ratio

2.16×

16th pctl of 20 SIC 3841 peers

Quick ratio

1.08×

Net cash

-$11.47B

Cash & equivalents minus total debt.

Piotroski F-Score

4 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

43.3xFair
42.4xmed 45.8x58.4x

P / S

Price / revenue per share

5.6xCheap
5.5xmed 6.1x6.6x

P / B

Price / book value per share

6.3xCheap
6.1xmed 6.8x7.2x

P / GP

Price / gross profit per share

8.8xCheap
8.7xmed 9.5x10.3x

P / FCF

Price / free cash flow per share

32.8xCheap
32.8xmed 38.9x49.6x

Dividend safety

Composite score

4.0 / 5

Strong
Payout ratio
39.6%4/5 Strong
FCF coverage
3.34×5/5 Strong
Dividend growth streak
10 yr5/5 Strong
Balance-sheet health
D/E 1.00 · IC N/A2/5 Fair

Capital allocation quality

Composite score

3.0 / 5

Good
Share count trend
0.2%2/5 Fair
Buyback timing
N/AN/A
Dividend growth consistency
10 yr5/5 Strong
Net debt trajectory
-4.0%2/5 Fair

Lifecycle Phase History

20202025
Value
Capital Return

Price History

SYK+2.9% · +0.6% CAGRSPY+84.0% · +12.9% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports